Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2006

Mentor and Genzyme to Partner on Hyaluronic Acid Dermal Fillers

  • Genzyme will develop future hyaluronic acid (HA) dermal filler products according to a commercialization agreement with Mentor.

    The first product launch under the agreement is scheduled to occur internationally in early 2007, with a worldwide launch of an additional product in late 2007.

    Genzyme and Mentor will join resources to develop a longer-lasting HA dermal filler. With Genzyme's history in HA development and manufacturing, Mentor has created a partnership that will allow its facial aesthetics pipeline to expand significantly. All the products will be introduced into Mentor's current distribution network, maximizing the revenue opportunity.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »